---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021479"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:41:14.964962+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q3 core lung diagnostic revenue up 102% to $9.2M; guidance at high end

## Summary
- Core lung diagnostic revenue $9.2M (+102% YoY); total revenue $11.1M (+70% YoY).
- Gross margin 67% vs 58% YoY, driven by growth in higher-margin core lung diagnostics.
- Net loss $13.7M (up 19% YoY); cash $15.2M; raised $1.8M via equity; repaid $2.0M term loan.
- All five core lung tests now covered by Medicare; added to Federal Supply Schedule for VA and Military Health.
- 2022 total revenue guidance expected at high end of $37.5M-$39.5M; minimal COVID/BioPharma in Q4.

## SEC filing metadata
- accession: 0000950170-22-021479
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/0000950170-22-021479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/bdsx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021479
- JSON: https://secwatch.observer/filing/0000950170-22-021479.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021479.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported third quarter ended September 30, 2022 results: revenue $11.1 million, net income $(0.34) per diluted share, EPS $(0.34) per diluted share. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Revenue: $11.1 million
  - Net income: $(0.34) per diluted share
  - EPS: $(0.34) per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: College of Chest Physicians (CHEST) annual meeting where we had several key presentations.” Third Quarter 2022 Financial Results For the three-month period ended September 30, 2022, as compared to the same period of 2021 (where applicable): • Total revenue of $11.1 million, an increase of 70%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $9.2 million, reflected a year-over-year increase of 102% driven primarily by the increased adoption of Nodify Lung nodule management tests (Nodify CDT & Nodify XL2 tests) and the recent GeneStrat NGS commercial launch; o COVID-19 testing revenue of $1.3 million reflected a year-over-year increase of 154% that was driven primarily by testing volume under a now expired contract with the State of Colorado; o BioPharma Services revenue of $0.7 million decreased 55% year-over-year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017022021479/0000950170-22-021479-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.